Loading organizations...
Loading organizations...
Key people at Forepont Capital Partners.
Forepont Capital Partners was founded in 2017 by Eric M. Attias (Managing Partner & Co-Founder).
Forepont Capital Partners is a global venture capital firm that invests in Bio&Med Tech startups across the United States and Europe. The firm provides capital alongside comprehensive scientific, technological, financial, and operational support to its portfolio companies, aiming to foster innovation within the healthcare and life sciences sectors. Its strategy involves active engagement to accelerate the development and market penetration of transformative health technologies.
The firm was founded in 2017 by Eric M. Attias, who holds roles as Chair, CIO, and founder. The central insight behind its establishment was to build strong, tight partnerships with industry leaders, including researchers, hospitals, academia, and large pharmaceutical groups. This network is crucial for generating proprietary deal flow and significantly enhancing the performance and strategic trajectory of its investments.
Forepont Capital Partners primarily targets early-stage companies in biotech, medtech, and digital health. The firm’s vision is to propel advancements in healthcare innovation by connecting its portfolio with vital resources and expertise. It focuses on identifying and nurturing companies developing technologies capable of addressing significant medical challenges and improving patient outcomes globally.
Forepont Capital Partners was founded in 2017 by Eric M. Attias (Managing Partner & Co-Founder).
Key people at Forepont Capital Partners.
# Forepont Capital Partners: Healthcare Innovation Through Strategic Venture Capital
Forepont Capital Partners is a global venture capital and asset management firm dedicated to advancing healthcare and life sciences innovation through strategic investments and operational support[1]. Founded in 2017 in New York, the firm operates as a specialized investor in biotech, medtech, and e-health startups across the United States and Europe[1].
The firm's mission centers on accelerating medical research and innovation, with particular emphasis on neurology and related therapeutic areas[1]. Rather than functioning as a passive capital provider, Forepont takes an active, hands-on approach to portfolio company development, offering scientific, technological, financial, and operational support to enhance performance and market positioning[1]. This comprehensive support model, combined with privileged access to healthcare partnerships and deep regulatory expertise across American and European markets, positions Forepont as a distinctive player in the healthcare venture ecosystem[1].
Forepont Capital Partners was established in 2017 in New York by founder Eric M. Attias, who serves as the firm's visionary leader[6]. The founding team includes key partners such as Bruce Greenberg (Partner and Chief Financial Officer) and Frederic Batoua (Partner), alongside venture partners like Larry Rubin[6].
The firm's evolution reflects a deliberate focus on building deep relationships within the healthcare ecosystem. Rather than pursuing broad venture investments, Forepont strategically cultivated strong partnerships with hospitals, universities, and large pharmaceutical groups from inception[2]. This relationship-first approach created a unique deal flow advantage and established the foundation for the firm's distinctive value proposition. The firm expanded its geographic footprint to include offices in Paris, London, Tel Aviv, and Palo Alto, assembling a team of 12 complementary experts supported by a robust network of scientific advisors[2]. To date, Forepont has invested in 13 companies, demonstrating disciplined capital deployment aligned with its specialized focus[2].
Forepont distinguishes itself through a comprehensive, all-in-one support model that extends far beyond capital provision. The firm provides scientific, technological, financial, and operational support to portfolio companies, leveraging its global ecosystem and expertise to enhance performance[1]. This includes hands-on assistance with finance, business development, and international expansion, as well as facilitating market entry for U.S. companies seeking European presence and vice versa[2].
The firm's established relationships with hospitals and universities generate privileged access to unique investment deal flow that competitors cannot easily replicate[2]. This network advantage ensures thorough consideration of medical, human, financial, and ethical factors before investment decisions, creating a quality filter that aligns with the firm's mission-driven approach[1].
With deep knowledge of American and European regulations, Forepont provides crucial support at both local and international levels[1]. This regulatory sophistication is particularly valuable for medtech and biotech companies navigating complex compliance landscapes across multiple jurisdictions.
Forepont has invested in modern portfolio management infrastructure to provide LPs with unprecedented transparency and self-service accessibility[2]. The firm recognizes that institutional investors increasingly demand real-time visibility into fund strategy implementation and investment performance, and has implemented solutions that empower LPs with on-demand, interactive access to portfolio information[2].
Forepont operates at the intersection of several powerful trends reshaping healthcare innovation. The convergence of aging populations, rising healthcare costs, and technological advancement has created unprecedented demand for novel therapeutic approaches and digital health solutions. The firm's focus on neurology—a field facing significant unmet medical needs—positions it to capture value from breakthrough innovations in neurodegenerative diseases, psychiatric disorders, and neurological conditions.
The venture capital landscape for healthcare has matured considerably since 2017, with increased institutional capital flowing into life sciences. However, most generalist venture firms lack the specialized expertise and healthcare relationships necessary to effectively support medtech and biotech companies through complex development cycles. Forepont's specialized positioning and integrated support model address this gap, allowing the firm to create outsized value for portfolio companies while generating superior returns for LPs.
The firm's emphasis on bridging U.S. and European markets reflects the globalization of healthcare innovation. Regulatory harmonization efforts, international clinical trial networks, and cross-border capital flows have made geographic flexibility a competitive advantage. Forepont's multi-office presence and expertise across regulatory regimes enable portfolio companies to scale internationally more efficiently than peers working with geographically constrained investors.
Forepont Capital Partners represents a sophisticated evolution in venture capital strategy—moving beyond capital provision toward integrated value creation in specialized domains. The firm's disciplined focus on healthcare and life sciences, combined with its deep ecosystem relationships and operational support capabilities, positions it well to identify and nurture transformative innovations in an increasingly capital-rich but expertise-scarce market.
Looking forward, several trends will likely shape Forepont's trajectory. The continued maturation of digital health and AI-enabled diagnostics will expand investment opportunities beyond traditional biotech. Regulatory pressures on drug pricing and healthcare costs will create demand for innovative business models and cost-effective solutions. The firm's international presence positions it to benefit from the emergence of biotech hubs outside traditional centers, particularly in Europe and Israel.
As healthcare innovation becomes increasingly complex and capital-intensive, specialized venture firms with genuine operational expertise and institutional relationships will command premium valuations and LP commitments. Forepont's early recognition of this trend and deliberate investment in building differentiated capabilities suggest the firm is well-positioned to expand its influence and capital under management in the coming years.
